Abstract
CHMP2B mutations are a rare cause of autosomal dominant frontotemporal dementia (FTD). The best studied example is frontotemporal dementia linked to chromosome 3 (FTD-3) which occurs in a large Danish family, with a further CHMP2B mutation identified in an unrelated Belgian familial FTD patient. These mutations lead to C-terminal truncations of the CHMP2B protein and we will review recent advances in our understanding of the molecular effects of these mutant truncated proteins on vesicular fusion events within the endosome-lysosome and autophagy degradation pathways. We will also review the clinical features of FTD caused by CHMP2B truncation mutations as well as new brain imaging and neuropathological findings. Finally, we collate the current data on CHMP2B missense mutations, which have been reported in FTD and motor neuron disease.
Keywords: Frontotemporal dementia, CHMP2B, endosome, lysosome, autophagy, brain imaging, neuropathology, CBD, FTLD-TDP, CHMP2BIntron5, CHMP2BDelta10, CHMP2BQ165X, lateral preponderance, MND, neurotransmitter receptors
Current Alzheimer Research
Title: Frontotemporal Dementia Caused by CHMP2B Mutations
Volume: 8 Issue: 3
Author(s): A. M. Isaacs, P. Johannsen, I. Holm, J. E. Nielsen and FReJA Consortium
Affiliation:
Keywords: Frontotemporal dementia, CHMP2B, endosome, lysosome, autophagy, brain imaging, neuropathology, CBD, FTLD-TDP, CHMP2BIntron5, CHMP2BDelta10, CHMP2BQ165X, lateral preponderance, MND, neurotransmitter receptors
Abstract: CHMP2B mutations are a rare cause of autosomal dominant frontotemporal dementia (FTD). The best studied example is frontotemporal dementia linked to chromosome 3 (FTD-3) which occurs in a large Danish family, with a further CHMP2B mutation identified in an unrelated Belgian familial FTD patient. These mutations lead to C-terminal truncations of the CHMP2B protein and we will review recent advances in our understanding of the molecular effects of these mutant truncated proteins on vesicular fusion events within the endosome-lysosome and autophagy degradation pathways. We will also review the clinical features of FTD caused by CHMP2B truncation mutations as well as new brain imaging and neuropathological findings. Finally, we collate the current data on CHMP2B missense mutations, which have been reported in FTD and motor neuron disease.
Export Options
About this article
Cite this article as:
M. Isaacs A., Johannsen P., Holm I., E. Nielsen J. and Consortium FReJA, Frontotemporal Dementia Caused by CHMP2B Mutations, Current Alzheimer Research 2011; 8 (3) . https://dx.doi.org/10.2174/156720511795563764
DOI https://dx.doi.org/10.2174/156720511795563764 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hydrophobic Plant Antioxidants. Preparation of Nanoparticles and their Application for Prevention of Neurodegenerative Diseases. Review and Experimental Data
Current Topics in Medicinal Chemistry Psoriasis and Atherosclerosis: Is There a Need For Novel Biomarkers Assessing Cardiovascular Risk?
Current Pharmaceutical Design FTD and ALS: A Tale of Two Diseases
Current Alzheimer Research Polypharmacology in a Single Drug: Multitarget Drugs
Current Medicinal Chemistry Principles of Clinical Management of Patent Ductus Arteriosus in Extremely Preterm Neonates
Current Pediatric Reviews Memory Impairment is Associated with Serum Methylarginines in Older Adults
Current Alzheimer Research Gonadotropin-Releasing Hormone Receptor System: Modulatory Role in Aging and Neurodegeneration
CNS & Neurological Disorders - Drug Targets Alzheimer’s Disease Brain Areas: The Machine Learning Support for Blind Localization
Current Alzheimer Research Hyperhomocysteinemia and Cardiovascular Risk: Effect of Vitamin Supplementation in Risk Reduction
Current Clinical Pharmacology The Histamine H3 Receptor as a Therapeutic Drug Target for Metabolic Disorders: Status, Challenges and Opportunities
Current Topics in Medicinal Chemistry Health Outcomes Associated with Hormone Therapy in Australian Women
Current Drug Safety Psychopharmacological Treatment in Pathological Gambling: A Critical Review
Current Pharmaceutical Design Tualang Honey and its Methanolic Fraction Improve LPS-induced Learning and Memory Impairment in Male Rats: Comparison with Memantine
Current Nutrition & Food Science Stroke Prevention: From Available Antiplatelet Drugs to Novel Molecular Targets
Current Drug Targets Amelioration of Dementia and Antioxidant Activity of <i>Holarrhena antidysenterica</i> Bark in Mice
Current Psychopharmacology A Population-Based Study of Cholesterol Measurements in the Oldest Old
Current Aging Science Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets Current Advances in Vehicles for Brain Gene Delivery
Current Gene Therapy NMR Structural Studies of Human Cellular Prion Proteins
Current Topics in Medicinal Chemistry The Therapeutic Potential of Rutin for Diabetes: An Update
Mini-Reviews in Medicinal Chemistry